MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

Similar documents
VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING

Section 5. Study Procedures

Section 5. Study Procedures

Section 5. Study Procedures

Overview of Enrollment/Initiate Period 1 Visit Procedures

Section 6. Participant Follow-up

Section 6. Participant Follow-up

Section 6. Participant Follow-up

Section 10 Counseling Considerations

Follow-up Visit Procedures MTN-009

Section 10. Counseling Procedures

VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

MTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018

Section 11. Counseling Procedures

QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing

Maintaining Participant Contact: June-December 2015 and Results dissemination

9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-035.

Clinical Considerations. Review

November 9, Clarification Memo 1 Version 3.0 HVTN 704/HPTN 085

Pre Exposure Prophylaxis Health Program

FHI Study 10015: FEM-PrEP

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

PrEP Home Checklist v1.0

FY 2018 PERFORMANCE PLAN. Public Health/ CHSB

An Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

December 14, Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085

Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University

SFAF CLINICAL PROTOCOLS

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313

APPENDIX A SERVICE SPECIFICATION

Figure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT)

Section 9. Laboratory Considerations

LESSON 9. How to counsel clients on Sayana Press self-injection

I M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep

Young People s Sexual Health Services. Pathways for Practitioners In Cambridgeshire

QUESTIONS AND ANSWERS

Patient Case Records Review

How Do You Survive In Today s Practice Environment?

Lessons from MSM PrEP pilots / demonstration projects. Kevin Rebe

Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers

2018 Preventive Schedule

2018 Preventive Schedule

Ensure access to and compliance with treatment for low-income uninsured Virginia residents living with HIV/AIDS

Specimen Management PHRU LAB

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

Non-Occupational Post-Exposure HIV Prophylaxis npep

HPTN 035. Laboratory Overview

PAEDIATRIC PROVIDER INITIATED TESTING AND COUNSELLING

Remind me, what s an STI? And why are they relevant to me?

Prescriber and Pharmacy Guide for the Tracleer REMS Program

Preventive Services Explained

ICAP Journal Club. Article. Study Summary

MTN-026 Clinical Management Overview

PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

Impact of Learning HIV Status on Contraceptive Use in the MIRA Trial

Ensure access to and compliance with treatment for low-income uninsured Virginia residents living with HIV/AIDS

How to order generic PrEP online Find a doctor who prescribes PrEP Learn how to prescribe PrEP Information for doctors. What is PrEP?

Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis

HEALTH BELIEF MODEL. The HBM is based on the understanding that a person will take a health-related action (i.e., use condoms) if that person:

Cleveland Prevention Update. Zach Reau HIV Prevention Program Manager Ohio Department of Health

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

ESSENTIAL PACKAGE FOR HIV CARE AND TREATMENT. Essential Package for HIV Care and Treatment

Section 8. Clinical Considerations

2019 Preventive Schedule Effective 1/1/2019

CANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management

TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers

VL patient support: General education at different levels

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

Fertility preservation for women wishing to freeze egg/ embryo for fertility preservation

Contraception for Women and Couples with HIV. Knowledge Test

2. Chapter 2: Eligibility

Blood Donor Counselling

2017 Preventive Schedule

2018 Preventive Schedule

HIV PrEP in Ireland. Information booklet for people who are accessing PrEP themselves or are considering accessing PrEP

CALM LEARNER OUTCOMES 1 :

SINDAWONYE Clinical Trials Unit

Counselling Should: Recognize that behaviour change is difficult and human beings are not perfect

The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016

2017 Wellness Program Guide. East Central College

FACT SHEET: Copper IUD

Visit 47 Training Document

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

MTN-020 In-depth Interview (IDI) Topic Guide

Prescriber and Pharmacy Guide for the Opsumit REMS Program

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

MANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE

2017 Preventive Schedule

Enhanced Adherence Counseling (EAC) for Adults

Percentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated

Adolescent HPV Prevalence Survey

Transcription:

MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

CLINIC CLERK Greet participant. Create rapport Confirm PTID with Screening and Enrollment Log vs Participant s appointment card Check co enrollment N.B If participant is not co enrolled proceed If co enrolled inform clinic manager medical officer IoR, immediately withhold study product use and seek assistance from the Protocol Safety Review Team (PSRT)

PHARMACY Greet participant Unused product supplies returned Check PTID and study product label

COUNSELLOR Verify participant s binder & review previous documentation Greet participant & assure confidentiality Review elements of the IC Explain the content and sequence of procedures for the day Review/ update locator information

RESEARCH NURSE Welcome and greetings Explain to participant procedures to be done Urine collection Questionnaire Physical exam Blood draw Collect urine for pregnancy test and urinalysis

Continued RESEARCH NURSE Dipstick urinalysis for protein and glucose Month 1 (Month 2 if clinically indicated). Dipstick urinalysis for nitrites and leukocyte esterase if clinically indicated. Negative pregnancy result proceed Positive pregnancy result inform clinic manager Complete a pregnancy Report and History Form Inform participant that she must stop product use and arrange to collect product supplies

Continued Research Nurse Collect interval medical and menstrual history Administer monthly Product Adherence and Behavior Assessment form Document accordingly

COUNSELLOR Pretest HIV counselling Aim is to prepare participant for any HIV test result. Reassure confidentiality Discuss basic facts about HIV and AIDS HIV/STI risk reduction Inform participant that results will be ready in about 20 40 minutes

RESEARCH NURSE Blood draw Month 1 1 x 5ml lavender top (ETDA) for HIV testing 1 x 5 ml red top tube for LFTs and RFTs Month 2 1 x 5 ml lavender top (ETDA) Transcribe HIV Test results N.B Verify results first before collection from lab

RESEARCH NURSE Perform and document physical exam and weight measurement Month 1 (Month 2 if clinically indicated) If clinically indicated, perform and document pelvic exam per follow up pelvic exam checklist Provide and explain all available findings and results

Continued Research nurse Contraceptive counselling and provide contraception per site SOP Provide treatment for STI for participant and partner if applicable Administer Hepatitis B vaccine if clinically indicated Complete AE log if required based on medical history, clinical examination and any results from the lab

Continued Research Nurse Assess eligibility to continue product use If eligible, provide product request slip, offer adherence counselling If ineligible, complete study product request slip marked Hold or Permanently Discontinued. Check if unused product has been returned to pharmacy Remind participant to bring all unused study product supplies and any medication she is currently taking

COUNSELLOR Post Test& Adherence Counselling Check if results are in the binder Call the participant and assure confidentiality Assess readiness to receive the HIV test results Inform participant and show her the result. If both tests are negative proceed. Discuss the meaning of result including the window period. Discuss risk reduction and partner testing issues, condom use. Offer study product adherence counselling

COUNSELLOR Continued Find out if she is using the study product correctly and consistently If there are any challenges on adherence, discuss how she can overcome them. Emphasise the importance of adhering to study product whilst in the study Inform participant to come back to the clinic if she has any symptoms and for more supplies Remind her to bring all unused product on next visit

COUNSELLOR Continued Positive Result Discuss meaning of results and implications to self, partner and family. Explore her feelings and address them accordingly. Inform participant that a WB test will be done on the same sample for confirmatory purposes. Inform her that she will stop product use and that she continues in the study.

COUNSELLOR Continued Discuss positive living issues Diet Risk reduction Health issues, psychological and physical Inform her that she is welcome for further counselling when needed. Offer condoms Inform clinic manager about the seroconversion

PHARMACY Product supply Adherence counselling based on product count Clinic manager informed if there are any challenging issues on adherence e.g. product sharing or selling before participant leaves the clinic

CLINIC CLERK Schedule next visit Complete registration Log Reimburse participant

Thank You! Bayadhanki! Zikomo! Siyabonga! Mwebale nnyo! Tatenda!